Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516542-19-00

Acronym

BioPhenoT2D

Enrollment

148

Registered

2024-10-09

Start date

2025-07-08

Completion date

Unknown

Last updated

2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Brief summary

To assess the differential effects of treatment with semaglutide vs dapagliflozin on metabolic compensation and beta-cell function – measured through glycated hemoglobin (HbA1c)

Detailed description

To verify the ability of biomarkers to offer a signature for patients’ phenotyping even after treatment with dapagliflozin or semaglutide, To verify the ability of biomarkers to guide the more appropriate choice between dapagliflozin or semaglutide treatments in well-distinguished phenotypes of diabetic patients

Interventions

DRUGDAPAGLIFLOZIN

DRUGSEMAGLUTIDE

DRUGINSULIN GLARGINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the differential effects of treatment with semaglutide vs dapagliflozin on metabolic compensation and beta-cell function – measured through glycated hemoglobin (HbA1c)	—

Secondary

Measure	Time frame
To verify the ability of biomarkers to offer a signature for patients’ phenotyping even after treatment with dapagliflozin or semaglutide, To verify the ability of biomarkers to guide the more appropriate choice between dapagliflozin or semaglutide treatments in well-distinguished phenotypes of diabetic patients	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026